The nutraceutical division will be responsible for white-label programs for companies interested in delivery formats such as gummies, effervescents, chewable tablets, oral film strips, to name a few.
Photo © AdobeStock.com/olindana
Star Manufacturing (San Diego, CA), a GMP, FDA facility, launched a nutraceutical division, Star Organics, that will be responsible for white-label programs for companies interested in:
Star Manufacturing authenticates ingredients using the TRU-ID certification program. The bio-markers are analyzed and fingerprinted to prevent adulteration and to deliver ingredients as pure as possible.
“Whether it is to build ecommerce sales or support brick-and-mortar, Star Organics is positioned to provide superior service and expertise to customers at all levels, including helping the small and midsized companies to turn best-in-class products and help them grow to the next level,” said Mark Forester, owner of Star Manufacturing, in a press release. “Every customer will find that service, quality, and integrity are the cornerstones of our company.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.